NKTR - Nektar Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NKTR is currently covered by 6 analysts with an average price target of $34.98. This is a potential upside of $5.86 (20.12%) from yesterday's end of day stock price of $29.12.

Nektar Therapeutics's activity chart (see below) currently has 136 price targets and 95 ratings on display. The stock rating distribution of NKTR is 57.14% HOLD, 28.57% BUY and 14.29% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 58.84% with an average time for these price targets to be met of 257.61 days.

Highest price target for NKTR is $6, Lowest price target is $2, average price target is $4.

Most recent stock forecast was given by ROGER SONG from JEFFERIES on 11-Apr-2025. First documented stock forecast 28-Jul-2014.

Currently out of the existing stock ratings of NKTR, 4 are a HOLD (57.14%), 2 are a BUY (28.57%), 1 are a SELL (14.29%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$2

$-6.51 (-76.50%)

$1.6

2 months 14 days ago
(11-Apr-2025)

5/5 (100%)

$1.38 (222.58%)

39

Hold

$6

$-2.51 (-29.49%)

$3

3 months 11 days ago
(14-Mar-2025)

5/6 (83.33%)

$5.1 (566.67%)

208

Buy

$4

$-4.51 (-53.00%)

8 months 26 days ago
(30-Sep-2024)

3/6 (50%)

$2.7 (207.69%)

186

Sell

1 years 7 months 5 days ago
(20-Nov-2023)

5/8 (62.5%)

$6.02 (54.83%)

121

Buy

$2

1 years 7 months 16 days ago
(09-Nov-2023)

1/4 (25%)

$0.61 (43.88%)

833

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NKTR (Nektar Therapeutics) average time for price targets to be met?

On average it took 257.61 days on average for the stock forecasts to be realized with a an average price target met ratio 58.84

Which analyst has the current highest performing score on NKTR (Nektar Therapeutics) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on NKTR (Nektar Therapeutics)?

Josh Schimmer works at EVERCORE and has 3 price targets and 2 ratings on NKTR

Which analyst is the currently most bullish on NKTR (Nektar Therapeutics)?

George Farmer with highest potential upside - $45.4

Which analyst is the currently most reserved on NKTR (Nektar Therapeutics)?

Roger Song with lowest potential downside - -$6.51

Nektar Therapeutics in the News

Q1 2025 Nektar Therapeutics Earnings Call

Participants Corinne Franklin; investor relation; Nektar Therapeutics Howard Robin; President, Chief Executive Officer, Director; Nektar Therapeutics Jonathan Zalevsky; Chief Research and Development Officer; Nektar Therapeutics Sandra Gardiner; Interim Chief Financial Officer; Nektar Therapeutics Dominic Risso-Gill Julian Harrison; Director; BTIG LLC Jay Olson Mayank Mamtani Jessica Fye; Analyst; JPMorgan Presentation Operator Good day and thank you...

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...

Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nektar Therapeutics (NASDAQ:NKTR) is advancing its immunology pipeline, focusing on ResPEGaldu leukin (ResPEG) in three separate phase 2 studies. The company plans to share top-line results from a 400-patient phase 2b study...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?